Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR19042 for primary IgA nephropathy
CTR20212072Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HR19042 in IgA nephropathy (IgAN), sponsored by Hengrui Therapeutics. Started Dec 2021; status: completed.
02
Drugs
HR19042
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20212072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212072.